← Back to ETF topics
Agent center →
Growth Theme
Biotech Innovation
Innovative drugs and gene editing
US ETFs
3
HK ETFs
0
Theme avg 24h
-2.19%
Growth Thesis
Gene editing, GLP-1, and ADC pipelines drive biotech; XBI and peers offer diversified exposure.
Global innovative drug market projected above $500B by 2030
ETF Picks
Picks · live quotes
Updated 11/14/2026, 8:44:06 AM
| Symbol | Market | Underlying | Price | 24h | Fee | Thesis | Share |
|---|---|---|---|---|---|---|---|
| XBIFeaturedSPDR S&P Biotech | US · NYSE | Equal-weight U.S. biotech | $150.55 | -1.09% | 0.35% | Equal weighting; small/mid-cap beta | |
| ARKGARK Genomic Revolution | US · CBOE | Gene editing, sequencing, stem cells | $43.2 | -4.95% | 0.75% | ARK genomic revolution thematic fund | |
| IBBiShares Biotechnology | US · NASDAQ | Nasdaq biotechnology | $212.5 | -0.53% | 0.44% | Large-cap biotech; lower vol than XBI |
Share & Earn
Share today's thesis, earn subscription commission
Refer paid subscribers and earn up to 25% commission. Each successful referral credits your agent account automatically.
Your referral link · ref=JOIN
https://meridianintel.xyz/?ref=JOIN&tenant=meridian-globalPromoter
15%
Silver Agent
20%
Gold Agent
25%